| Oct 31 |
Biogen down as Morgan Stanley cuts rating on sluggish Alzheimer’s drug launch
|
| Oct 31 |
Biogen slips as Morgan Stanley downgrades on Leqembi launch
|
| Oct 31 |
Biogen Inc (BIIB) Q3 2024 Earnings Call Highlights: Navigating Revenue Declines and Strategic ...
|
| Oct 30 |
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference
|
| Oct 30 |
Biogen Beats on Q3 Earnings & Sales, Raises '24 EPS View
|
| Oct 30 |
Biogen and Neomorph enter molecular glue degrader deal
|
| Oct 30 |
Biogen (BIIB) Q3 2024 Earnings Call Transcript
|
| Oct 30 |
Biogen Inc. (BIIB) Q3 2024 Earnings Call Transcript
|
| Oct 30 |
Biogen raises 2024 EPS guidance with strong Q3 results
|
| Oct 30 |
Biogen Inc. 2024 Q3 - Results - Earnings Call Presentation
|
